Why You Don't Need to Cycle CJC-1295 or Tesamorelin

The cycling advice for CJC-1295 and Ipamorelin almost universally treats them as a single compound because they come pre-mixed in the same vial. But they are not a single compound, and they do not work through the same system, and conflating them has led to one of the most repeated misunderstandings in peptide protocols: the idea that you need to cycle off CJC or tesamorelin to preserve your response to them.

To understand why that is wrong, you need to understand how growth hormone is controlled in the first place.

Your pituitary gland produces growth hormone, but it does not decide on its own when to do that. It takes instructions from the hypothalamus through two separate chemical signals. The first is something called GHRH, or growth hormone releasing hormone, which tells the pituitary to produce and release growth hormone. The second is something called ghrelin, which works through an entirely different receptor pathway to amplify that signal. Think of GHRH as the gas pedal and ghrelin as a turbocharger. They work together, but they are mechanically separate, and what happens to one does not automatically happen to the other.

CJC-1295 and tesamorelin are both GHRH analogs, meaning they mimic the natural GHRH signal and bind to GHRH receptors. Ipamorelin is a ghrelin mimetic, meaning it binds to ghrelin receptors. Same downstream output, completely different receptor systems.

Now here is where the biology matters.

When you stimulate a receptor continuously, your body has a defense mechanism that prevents it from being overloaded. It starts pulling receptors off the surface of cells through a process called beta-arrestin mediated internalization, which is basically the cell physically removing receptors from its outer wall so they cannot receive signals anymore. Fewer surface receptors means a weaker response to the same dose. This is called receptor downregulation, and it is a real phenomenon with real consequences.

This is exactly what happens with continuous Ipamorelin use. A 16-week human trial tracked growth hormone response in subjects receiving continuous ghrelin receptor stimulation and found that GH output declined about 45 percent from baseline by week 16. When they stopped for four weeks, the response came all the way back to where it started. The receptors had time to return to the surface. That recovery window is the whole reason you cycle Ipamorelin, typically three months on and one month off, and it is a real physiological necessity, not a precaution.

So the question is whether the same thing happens to GHRH receptors when you stimulate them continuously.

It does not, and there is a structural reason why.

Tesamorelin has a half-life of roughly 30 minutes. You inject it once daily, it binds to GHRH receptors, sends a signal, and is cleared from the system. By the time the next dose arrives roughly 24 hours later, those receptors have had more than 23 hours to recover, recycle back to the cell surface, and reset. The receptor is not being held in a stimulated state. It is getting a brief pulse and then a long rest.

This matters because beta-arrestin mediated internalization requires sustained receptor occupancy to drive meaningful downregulation. A brief signal followed by a long recovery period does not produce the same receptor depletion as continuous or near-continuous stimulation.

The clinical data reflects this directly. In the Phase 3 trials supporting FDA approval of tesamorelin, subjects received daily injections for 52 weeks straight, and IGF-1 levels, which serve as a proxy for sustained growth hormone output, held steady through the entire 52 weeks with no measurable decline. No cycling. No breaks. No attenuation of response.

An earlier trial published in the New England Journal of Medicine showed the same pattern over 26 weeks of daily dosing, with sustained IGF-1 elevation maintained throughout without erosion of effect.

The independence of these two receptor systems has also been confirmed at the cellular level. Research using perifused rat pituitary cells demonstrated that stimulating GHRH receptors to the point of desensitization had no effect on the response from ghrelin receptors, and vice versa. The two systems do not interfere with each other and do not cross-desensitize. Whatever happens to one receptor population does not bleed over into the other.

There is also data from a two-year study on MK-677, which is an oral ghrelin mimetic that works through the same receptor system as Ipamorelin. In that trial, GH and IGF-1 levels were maintained for the full two years of continuous use. That finding is worth noting carefully, because it appears to contradict the desensitization pattern seen in shorter ghrelin receptor trials. The discrepancy is not fully resolved in the literature, and it may relate to dose, pulsatility, or inter-individual variation in receptor kinetics. The evidence here is not uniform, and that deserves acknowledgment rather than a clean narrative in either direction.

What the evidence does support clearly is this: the cycling recommendation that gets applied to CJC and tesamorelin does not come from data on those compounds. It comes from data on ghrelin receptor agonists, and it gets incorrectly extended to GHRH receptor agonists because people combine them in the same vial and treat them as one thing.

If you are running CJC and Ipamorelin together, you cycle because of the Ipamorelin. The CJC is along for the ride on that cycle, and it does not need to be. If you are running tesamorelin alone, the published evidence from over a year of continuous clinical use does not show a reason to cycle off it.

Most cycling advice is inherited, not derived. Someone decided to cycle one peptide, someone else blended it with a different one, and the rule transferred over without anyone checking whether it applied. That is how a recommendation built on ghrelin receptor biology became the standard advice for a compound that does not use ghrelin receptors at all.

---

References

1. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
2. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
3. FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
4. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
5. Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness